✦ LIBER ✦

The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities

✍ Scribed by Mingote, Laia Ruiz; Namutamba, Dorothy; Apina, Francis; Barnabas, Nomampondo; Contreras, Carmen; Elnour, Taharqa; Frick, Mike Watson; Lee, Cynthia; Seaworth, Barbara; Shelly, Debra; Skipper, Natalie; dos Santos Filho, Ezio Tavora

Book ID: 126866012
Publisher: The Lancet
Year: 2015
Tongue: English
Weight: 57 KB
Volume: 385
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(14)60523-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Review of the Evidence for Using Bedaq

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis

✍ Gregory J. Fox, Dick Menzies 📂 Article 📅 2013 🏛 Springer Healthcare Communications 🌐 English ⚖ 600 KB

A Review of the Evidence for Using Bedaq

A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis

✍ Gregory J. Fox, Dick Menzies 📂 Article 📅 2013 🏛 Springer Healthcare Communications 🌐 English ⚖ 600 KB

Existing therapies for multi-drug resistant tuberculosis (MDR-TB) have substantial limitations, in terms of their effectiveness, side-effect profile, and complexity of administration. Bedaquiline is a novel diarylquinoline antibiotic that has recently been investigated as an adjunct to existing ther